3billion and Polish Rare Disease Foundation P4P Sign MOU to Enhance Diagnostic Access for Rare Lung Disease Patients

• Joint AI-based diagnostic project with Poland’s rare disease patient organization, Fundacja People4People (P4P)
• Collaboration aims to improve accuracy and accessibility of rare lung disease diagnosis through patient-driven initiatives

AI-based rare disease diagnostics company 3billion (CEO Changwon Keum) announced that it has signed a Memorandum of Understanding (MOU) with Poland’s rare disease patient organization Fundacja People4People (P4P) to collaborate on genetic testing for patients with rare lung diseases.

The partnership aims to expand diagnostic opportunities for patients with rare lung disorders and to enhance diagnostic accuracy and accessibility through AI-powered genomic analysis. Under this agreement, 3billion and P4P will jointly conduct a whole-exome sequencing (WES)-based diagnostic project for patients with rare lung diseases, leveraging P4P’s patient-driven funding program in Poland.

P4P is a non-profit organization dedicated to research and patient support across rare genetic and pulmonary disorders, encompassing activities from diagnosis and disease modeling to therapeutic development. The organization is an official partner of Polska Sieć Badań Klinicznych (the Polish Clinical Research Network) and is recognized for its national research infrastructure and collaborative network in the field of rare diseases.

Changwon Keum, CEO of 3billion, said the partnership represents an important step toward building a patient-centered diagnostic support model in collaboration with a global patient organization. He added that through 3billion’s AI-powered genomic interpretation technology, the company aims to enhance the accuracy of early diagnosis for rare lung diseases and actively support faster diagnosis and treatment for more patients across Poland, a country of approximately 40 million people.

Prof. Aleksandra Jezela-Stanek, Vice-president of P4P, noted that 3billion is a trusted partner providing innovative genetic diagnostic services to rare disease patients worldwide. She added that the collaboration is expected to help Polish patients with rare lung diseases identify genetic causes more quickly and receive timely and accurate diagnoses.

Both parties plan to extend their cooperation beyond this project to include joint research initiatives and broader patient-support programs that advance precision medicine for rare diseases.